Seeing Is Believing
Currently out of the existing stock ratings of Alan Carr, 76 are a BUY (93.83%), 3 are a HOLD (3.7%), 2 are a SELL (2.47%).
Analyst Alan Carr, carries an average stock price target met ratio of 67.99% that have a potential upside of 33.05% achieved within 380 days. Previously, Alan Carr worked at NEEDHAM.
Alan Carr’s has documented 169 price targets and ratings displayed on 27 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on CRSP, Crispr Therapeutics AG at 12-May-2022.
Analyst best performing recommendations are on GNCA (GENOCEA BIOSCIENCES).
The best stock recommendation documented was for GNCA (GENOCEA BIOSCIENCES) at 3/5/2014. The price target of $176 was fulfilled within 2 days with a profit of $45.04 (34.39%) receiving and performance score of 171.96.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$93
$23.85 (34.49%)
$78
6 days ago
(16-Oct-2025)
2/6 (33.33%)
$23.85 (34.49%)
32
Buy
$81
$11.85 (17.14%)
$81
13 days ago
(09-Oct-2025)
8/24 (33.33%)
$7.93 (10.85%)
214
Buy
$80
$10.85 (15.69%)
$80
1 months ago
(22-Sep-2025)
4/6 (66.67%)
$19.24 (31.67%)
100
Hold
$56
$-13.15 (-19.02%)
$42
2 months 17 days ago
(05-Aug-2025)
15/18 (83.33%)
$-0.34 (-0.60%)
131
Hold
$42
$-27.15 (-39.26%)
$38
2 months 18 days ago
(04-Aug-2025)
12/14 (85.71%)
$-13.59 (-24.45%)
164
What Year was the first public recommendation made by Alan Carr?